- After stumbling throughout much of 2021 and early 2022 to meet analyst expectations, INFU has righted the ship and looks to have a strong back half of 2022 in store.
- Investors seemed to have been spooked by a delay in finalizing a contract with GE Healthcare, but the now-revealed details of the situation are extremely bullish.
- The company has been aggressive in buying back shares and hinted at the possibility of that program continuing to take advantage of current low prices.
- Management clearly signaled, on multiple occasions during their 1Q22 conference call, that their strong guidance still provides plenty of room for them to outperform those expectations.
- Once the company is officially removed from the Russell 2000 index, the stock should be free to climb to a more reasonable valuation, with at least 55%-90% near-term upside potential.
For further details see:
InfuSystem Business Is Back On Track